Biomarkers in NASH Drug Development: Using Cytokeratin 18 as a Secondary Endpoint in Clinical Trials
October 22, 2018 - Toronto ON CAXtalks
fbonilla@xtalks.com
Phone:4169776555
Non-alcoholic fatty liver disease (NAFLD) is a medical condition characterized by the build-up of fat in the liver. NAFLD has a spectrum that ranges from steatosis and non-alcoholic steatohepatitis (NASH) to fibrotic NASH and cirrhosis.
This website uses cookies to ensure you get the best experience on our website. Learn more